Cardiac hypertrophy is traditionally treated with compounds that target cell surface receptors such as β-adrenergic receptors and angiotensin receptors (McKinsey and Kass, 2007; Schiattarella and Hill, 2015). This evidence concerns the gene CD177 and cardiac hypertrophy.